← Back to patent-cliff list
CAS 1616367-18-0
(1R,3S)-3-(3-ethoxy-4-methoxyphenyl)-1-phenyl-2,3-dihydro-1H-naphtho[1,2-e][1,3]oxazine
Codes: APER-013
Application context (from source-drug indications)
Plaque psoriasisApremilastBehçet's syndromeApremilastOral ulcerApremilastPsoriasisApremilastPsoriatic arthritisApremilast
Source drugs (routes using this intermediate)
| Drug | Tier | Expiry |
|---|---|---|
| Apremilast | Tier B — Position early | 2028 |
Position in synthesis routes (up/downstream chain)
Ordered by route registration; left → right is the synthesis direction. The highlighted node is the current CAS; others link to their own profiles.
3-ethoxy-4-methoxybenzaldehyde→N-(1,3-dioxo-1,3-dihydroisobenzofuran-4-yl)acetamide→(R)-1-(amino(phenyl)methyl)naphthalen-2-ol→(1R,3S)-3-(3-ethoxy-4-methoxyphenyl)-1-phenyl-2,3-dihydro-1H-naphtho[1,2-e][1,3]oxazine→lithium (methylsulfonyl)methanide→1-((R)-(((S)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl)amino)(phenyl)methyl)naphthalen-2-ol→(S)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethanamine
Intermediates available on this site
No listed intermediates for this target yet — send an RFQ directly and it will enter our matching pool.
This is a CAS-level registry record: registrations across routes are merged. Supplier offers and buyer demands will be matched on this CAS as the primary key.